Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | GLS2 | Q9UI32 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6898154 | 0.98 | ACHE (0.46) | ACHEBACE1PTGS2ALOX5PTPN1 | |
| SCHEMBL243893 | 0.98 | ACHE (0.46) | ACHEBACE1PTGS2ALOX5PTPN1 | |
| SCHEMBL6901931 | 0.98 | ACHE (0.46) | ACHEBACE1PTGS2ALOX5PTPN1 | |
| SCHEMBL6903485 | 0.98 | ACHE (0.46) | ACHEBACE1PTGS2ALOX5PTPN1 | |
| SCHEMBL27482175 | 0.98 | ACHE (0.46) | ACHEBACE1PTGS2ALOX5PTPN1 | |
| SCHEMBL11543697 | 0.98 | ACHE (0.46) | ACHEBACE1PTGS2ALOX5PTPN1 | |
| SCHEMBL6896832 | 0.98 | ACHE (0.46) | ACHEBACE1PTGS2ALOX5PTPN1 | |
| SCHEMBL1150883 | 0.94 | ACHE (0.36) | ACHEBACE1PTGS2ALOX5PTPN1 | |
| Acetic Acid SCHEMBL9004840 | 0.91 | GAA (0.39) | ACHEBACE1GAAHTTGPR84 | |
| Cyclopentanone SCHEMBL28849888 | 0.90 | ACHE (0.40) | ACHEBACE1PTGS2ALOX5PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 747 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4321501-B1 | METHOD FOR SYNTHESIZING DIMETHYL 3-(3-OXO-2-PENTYL)CYCLOPENTYLMALONATE AND CATALYST | ZHEJIANG XINHUA CHEMICAL CO LTD (CN) | 2025-10-01 | — | — | EP | claimed |
| US-20250287942-A1 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-18 | — | — | US | claimed |
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | claimed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | claimed |
| EP-4510829-A2 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | The Regents of University of California (US) | 2025-02-26 | — | — | EP | claimed |
| CN-119125413-A | Method for rapidly identifying grass carp variety and muscle characteristic flavor substances based on GC×GC-TOFMS technology | 湖南师范大学 | 2024-12-13 | — | — | CN | claimed |
| US-20240409490-A1 | SYNTHETIC METHOD AND CATALYST OF 3-(3-OXO-2-PENTYL)CYCLOPENTYL DIMETHYL MALONATE | Ningxia Xinhua Chemical Co., Ltd. (CN) | 2024-12-12 | — | — | US | claimed |
| CN-117964485-A | Method for preparing cis (1R, 2S) -methyl dihydrojasmonate by asymmetric catalytic hydrogenation | 上海交通大学 | 2024-05-03 | — | — | CN | claimed |
| EP-4356894-A1 | SUSTAINABLE PRODUCT WITH MALODORS | Beiersdorf AG (DE) | 2024-04-24 | — | — | EP | claimed |
| CN-114349640-B | Synthesis method of methyl dihydrojasmonate or intermediate thereof and catalyst used in synthesis method | 山东新和成药业有限公司 | 2024-03-22 | — | — | CN | claimed |
| US-5962706-A | ORGANOLEPTICS | FIRMENICH SA (CH) | 1999-10-05 | — | — | US | claimed |
| EP-0841331-A2 | New epoxides, process for their preparation and their use for the preparation of perfume ingredients | FIRMENICH SA (CH) | 1998-05-13 | — | — | EP | claimed |
| EP-0810903-A1 | RUTHENIUM CATALYSTS AND USE THEREOF IN ASYMMETRICAL CYCLOPENTENONE HYDROGENATION | FIRMENICH SA (CH) | 1997-12-10 | — | — | EP | claimed |
| WO-1997018894-A1 | RUTHENIUM CATALYSTS AND USE THEREOF IN ASYMMETRICAL CYCLOPENTENONE HYDROGENATION | FIRMENICH S.A. (CH) | 1997-05-29 | — | — | WO | claimed |
| US-5618982-A | SIMPLE INDUSTRIAL PROCESS OF CATALYZING IN PRESENCE OF METALLIC PHOSPHATES | RHONE-POULENC CHIMIE (FR) | 1997-04-08 | — | — | US | claimed |
| EP-0110142-B1 | PROCESS FOR THE PREPARATION OF ALKYLATED CYCLOPENTENONES, AND ACETYLENIC ESTERS USEFUL AS STARTING COMPOUNDS IN SAID PREPARATION | FIRMENICH SA (CH) | 1986-12-30 | — | — | EP | claimed |
| US-4499297-A | CYCLIZATION AND REARRANGEMENT OF AN 1-ALKYNYL-2-ALKYL-2-PROPENYL ESTER USING A NOBLE METAL HALIDE-NITRILE CATALYST | FIRMENICH, SA (CH) | 1985-02-12 | — | — | US | claimed |
| EP-0110142-A2 | Process for the preparation of alkylated cyclopentenones, and acetylenic esters useful as starting compounds in said preparation | FIRMENICH SA (CH) | 1984-06-13 | — | — | EP | claimed |
| US-4329508-A | Process for making alkyl cyclopentenones | SCM CORPORATION (US) | 1982-05-11 | — | — | US | claimed |
| US-4092362-A | HYDROLYSIS, DECAROXYLATION | ROURE S.A., A FRENCH CORP. (FR) | 1978-05-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250287942-A1 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | ACHE, BCHE, DDT | ACHE 1/4885BACE1 380/4885PTGS2 3674/4885 |
| US-20240409490-A1 | SYNTHETIC METHOD AND CATALYST OF 3-(3-OXO-2-PENTYL)CYCLOPENTYL DIMETHYL MALONATE | MVD, FDPS, PPIP5K2 | ACHE 3145/4885BACE1 4277/4885PTGS2 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.